Cargando…
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600059/ https://www.ncbi.nlm.nih.gov/pubmed/36290844 http://dx.doi.org/10.3390/curroncol29100567 |
_version_ | 1784816747271946240 |
---|---|
author | O’Sullivan, Dylan E. Jarada, Tamer N. Yusuf, Amman Hu, Leo (Xun Yang) Gogna, Priyanka Brenner, Darren R. Abbie, Erica Rose, Jennifer B. Eaton, Kiefer Elia-Pacitti, Julia Ewara, Emmanuel M. Pabani, Aliyah Cheung, Winson Y. Boyne, Devon J. |
author_facet | O’Sullivan, Dylan E. Jarada, Tamer N. Yusuf, Amman Hu, Leo (Xun Yang) Gogna, Priyanka Brenner, Darren R. Abbie, Erica Rose, Jennifer B. Eaton, Kiefer Elia-Pacitti, Julia Ewara, Emmanuel M. Pabani, Aliyah Cheung, Winson Y. Boyne, Devon J. |
author_sort | O’Sullivan, Dylan E. |
collection | PubMed |
description | Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013–2019, 2974 individuals underwent EGFR testing, of which 451 (15.2%) were EGFR positive. Among EGFR positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was gefitinib or afatinib monotherapy for individuals with Exon 19 (93.4%) and L858R (94.1%) mutations versus platinum combination therapy for individuals with Exon20ins mutations (61.5%). The Exon20ins cohort had worse median overall survival from initiation of 1L systemic therapy (10.5 months [95% CI: 8.0-not estimable]) than the Exon19 (20.6 months [95% CI: 18.4–24.9]), and L858R cohorts (19.1 months [95% CI: 14.5–23.1]). These findings highlight that Exon20ins mutations represent a rare subset of NSCLC in which treatment options are limited and survival outcomes are worse relative to individuals with more common types of EGFR mutations. |
format | Online Article Text |
id | pubmed-9600059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96000592022-10-27 Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers O’Sullivan, Dylan E. Jarada, Tamer N. Yusuf, Amman Hu, Leo (Xun Yang) Gogna, Priyanka Brenner, Darren R. Abbie, Erica Rose, Jennifer B. Eaton, Kiefer Elia-Pacitti, Julia Ewara, Emmanuel M. Pabani, Aliyah Cheung, Winson Y. Boyne, Devon J. Curr Oncol Article Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate EGFR testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013–2019, 2974 individuals underwent EGFR testing, of which 451 (15.2%) were EGFR positive. Among EGFR positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was gefitinib or afatinib monotherapy for individuals with Exon 19 (93.4%) and L858R (94.1%) mutations versus platinum combination therapy for individuals with Exon20ins mutations (61.5%). The Exon20ins cohort had worse median overall survival from initiation of 1L systemic therapy (10.5 months [95% CI: 8.0-not estimable]) than the Exon19 (20.6 months [95% CI: 18.4–24.9]), and L858R cohorts (19.1 months [95% CI: 14.5–23.1]). These findings highlight that Exon20ins mutations represent a rare subset of NSCLC in which treatment options are limited and survival outcomes are worse relative to individuals with more common types of EGFR mutations. MDPI 2022-09-30 /pmc/articles/PMC9600059/ /pubmed/36290844 http://dx.doi.org/10.3390/curroncol29100567 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article O’Sullivan, Dylan E. Jarada, Tamer N. Yusuf, Amman Hu, Leo (Xun Yang) Gogna, Priyanka Brenner, Darren R. Abbie, Erica Rose, Jennifer B. Eaton, Kiefer Elia-Pacitti, Julia Ewara, Emmanuel M. Pabani, Aliyah Cheung, Winson Y. Boyne, Devon J. Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title_full | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title_fullStr | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title_full_unstemmed | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title_short | Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers |
title_sort | prevalence, treatment patterns, and outcomes of individuals with egfr positive metastatic non-small cell lung cancer in a canadian real-world setting: a comparison of exon 19 deletion, l858r, and exon 20 insertion egfr mutation carriers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600059/ https://www.ncbi.nlm.nih.gov/pubmed/36290844 http://dx.doi.org/10.3390/curroncol29100567 |
work_keys_str_mv | AT osullivandylane prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT jaradatamern prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT yusufamman prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT huleoxunyang prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT gognapriyanka prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT brennerdarrenr prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT abbieerica prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT rosejenniferb prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT eatonkiefer prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT eliapacittijulia prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT ewaraemmanuelm prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT pabanialiyah prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT cheungwinsony prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers AT boynedevonj prevalencetreatmentpatternsandoutcomesofindividualswithegfrpositivemetastaticnonsmallcelllungcancerinacanadianrealworldsettingacomparisonofexon19deletionl858randexon20insertionegfrmutationcarriers |